The strategies of anti-PD-1/PD-L1 immunotherapy aim to preserve the antitumor capacity of T cells by overcoming the PD-1/PD-L1 interaction, thereby inhibiting the immune escape of tumor cells. This evidence concerns the gene CD274 and neoplasm.